Clinical trials: Covid19 Vaccination
Covid19, Kidney Diseases
RECOVAC Repeated Vaccination Study
Rationale: The humoral and cellular immune response after two mRNA vaccinations is severely attenuated in kidney transplant patients compared to controls, especially when their immunosuppressive regimen contains mycophenolate…
- Conditions
- Covid19, Kidney Diseases, Vaccine Response Impaired, SARS-CoV2 Infection
- Trial name
- NCT05030974
- Testing
- mRNA-1273, Ad26.COV2.S vaccine
- Where
- 4 sites in Netherlands
- Volunteers
- 336 people
- Sponsor
- University Medical Center Groningen
COVID-19, Vaccine Hesitancy
Addressing COVID-19 Vaccine Hesitancy With Muliti-Level Interventions in Appalachia
The purpose of this community-engaged study is to test the ability of county-level strategies to increase uptake of COVID-19 vaccination.
- Trial name
- K-VAC (NCT06505993)
- Testing
- Health Communication, Health Communication + Structural
- Where
- United States
- Volunteers
- healthy volunteers welcome
- Sponsor
- Marc Kiviniemi
Safety, Vaccine Reaction
Phase-I Study to Evaluate the Safety and Immunogenicity of a Prophylactic pDNA Vaccine Candidate Against COVID-19 in Healthy Adults
A pneumonia of unknown cause detected in Wuhan, China, was first reported in December 2019. On 08 January 2020, the pathogen causing this outbreak was identified as a novel coronavirus 2019.
- Conditions
- Safety, Vaccine Reaction, Vaccine Adverse Reaction, Immunization; Infection
- Trial name
- NCT05171946
- Testing
- S.opt.FL COVID-19 pDNA vaccine
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Iman Almansour
Immunogenicity, Efficacy
New Generation mRNA Booster Vaccine Against Emerging VOCs
Primary：Objectives ：SafetyTo describe the safetyprofile of all participants in each group up to 6months post-dose.Immunogenicity：To demonstrate the superiorityof neutralizing antibodyresponse in terms of geometric mean titers…
- Conditions
- Immunogenicity, Efficacy, Safety
- Trial name
- NCT05580159
- Testing
- SW-BIC-213, SARS-Cov-2 Vaccina(Vero Cell ) Inactivated
- Where
- Laos
- Volunteers
- 2,000 people, healthy volunteers welcome
- Sponsor
- Stemirna Therapeutics
Herpes Zoster
A Study on the Immune Response and Safety of the Shingles Vaccine and the Influenza Vaccine When Either is Given to Healthy Adults at the Same Time or Following a COVID-19 Booster Vaccine
The aim of this study was to evaluate the immune response and safety of both GlaxoSmithKline Biologicals SA's (GSK's) herpes zoster (HZ) subunit (su) vaccine in healthy adults 50 years of age (YOA) and older and quadrivalent…
- Trial name
- NCT05047770
- Testing
- HZ/su, Flu D-QIV, mRNA-1273
- Where
- 46 sites in United States
- Volunteers
- 2,013 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
COVID-19 Immunization, Influenza Immunization
Study of a Combination Vaccine Comprised of Different Recombinant Spike Antigen Levels of a Matrix-M Adjuvanted Recombinant COVID-19 Vaccine and High-Dose Inactivated Influenza Vaccine in Adult Participants 50 Years of Age and Older
Study VBT00001 is planned to be a Phase 1/2, randomized, modified double-blind, active-controlled, multi-center study to be conducted in approximately 980 adults aged 50 years and older in the United States.
- Trial name
- NCT06695117
- Testing
- IIV-HD, rC19 (dose 1), IIV-HD + rC19 (dose 1)
- Where
- 12 sites in United States
- Volunteers
- 980 people, healthy volunteers welcome
- Sponsor
- Sanofi
COVID-19
Working Towards Empowered Community-driven Approaches to Increase Vaccination and Preventive Care Engagement
This study will optimize, implement, and test the impact of our multicomponent health program that includes three primary implementation strategies (Cultural Weavers and co-creation, mHealth strategies using culturally meaningful…
- Trial name
- WEAVE (NCT05841810)
- Testing
- mHealth Outreach, Care Coordination
- Where
- 4 sites in United States
- Volunteers
- 398 people, healthy volunteers welcome
- Sponsor
- University of California, San Diego
COVID-19
Message Encouraging Vaccination in Preparation for the Holidays
This experiment is part of a megastudy with a total of ten experimental conditions and a holdout control condition to which patients will be randomly assigned.
- Trial name
- NCT05612360
- Testing
- COVID Booster text messages
- Where
- United States
- Volunteers
- 520,000 people, healthy volunteers welcome
- Sponsor
- University of Pennsylvania
Effect of Drug
Antenatal COVID 19 Vaccination and Pregnancy Outcomes
Effect of COVID 19 vaccinations on pregnancy outcomes must be clear and identified to detect their safty
- Trial name
- NCT05401825
- Testing
- pfizer, astrazeneca,moderna,sinofac
- Where
- Egypt
- Volunteers
- 162 people
- Sponsor
- Ain Shams University
Coronavirus Infections
Prospective Monitoring of BNT162b2 Second Vaccination Booster Effects in Health Care Workers (HCW)
The SARS-CoV-2 virus causes severe respiratory illness and is an ongoing global pandemic. On December 12, 2020 the FDA approved Pfizer's BioNTech vaccine BNT162b2 which is a messenger RNA type of vaccine for use.
- Trial name
- NCT05516459
- Testing
- Pfizer BNT162b2 Vaccine
- Where
- Israel
- Volunteers
- 635 people, healthy volunteers welcome
- Sponsor
- Soroka University Medical Center
Adult Who Received a First Dose of an mRNA Vaccine (Pfizer-BioNTech or Moderna) and Need to Receive a Second Dose
Compare Immunological Efficacy of a Vaccine Regimen Combining Two Covid19 mRNA Vaccines (Pfizer-BioNTech and Moderna) With That of a Homologous Vaccination of Each Covid19 mRNA Vaccine
As part of the COVID 19 vaccine campaign, the two mRNA vaccines, BNT162b2 (COMIRNATY®) and mRNA-1273 COVID-19 vaccine Moderna, are administered in two doses in subjects without a history of SARS-CoV-2 infection .
- Trial name
- ARNCOMBI (NCT04900467)
- Testing
- Pfizer, Moderna
- Where
- France
- Volunteers
- 418 people, healthy volunteers welcome
- Sponsor
- Assistance Publique - Hôpitaux de Paris
COVID-19
Incidence of COVID-19 Following Vaccination in Botswana Against SARS CoV 2
The AstraZeneca Study is a single-arm, open-label, interventional, Phase 3b study to determine the incidence of laboratory-confirmed COVID-19 hospitalizations, disease severity, and deaths and attributable adverse events (AEs) in…
- Trial name
- NCT05715944
- Testing
- AZD 1222
- Where
- Botswana
- Volunteers
- 10,888 people, healthy volunteers welcome
- Sponsor
- Botswana Harvard AIDS Institute Partnership
Covid19, Vaccines
Text-based Interventions to Promote COVID-19 Vaccinations
This study investigates whether and which type of text-based interventions affect the take-up of the COVID-19 vaccine.
- Trial name
- NCT04800965
- Testing
- Patient MyChart Scheduling Link, Patient Educational Video, Enhanced Follow through Message
- Where
- United States
- Volunteers
- 200,000 people, healthy volunteers welcome
- Sponsor
- University of California, Los Angeles
Vaccine Preventable Disease
COVID-19 Vaccine For Indirect Protection
The primary objective of this study is to test whether vaccinating adults ≥18 years in Hutterite colonies with mRNA-1273 (Moderna COVID-19) vaccine as compared to control (usual care) can prevent RT-PCR confirmed COVID-19 in…
- Trial name
- NCT04818736
- Testing
- COVID-19 Vaccination, Usual care
- Where
- Canada
- Volunteers
- healthy volunteers welcome
- Sponsor
- McMaster University
Covid19
Mucosal Immunity in Terms of SARS-CoV-2 Antibodies in Saliva After COVID-19 Infection and Vaccination
The Primary Objective of This Single-center Study is to Investigate the SARS-CoV-2 Spike Glycoprotein RBD Antibody Concentration in Saliva and Serum in Healthy Non Vaccinated and Non-SARS-CoV-2 Infected, COVID-19 Convalescents…
- Trial name
- NCT04842305
- Testing
- Blood- and saliva tests
- Volunteers
- 500 people, healthy volunteers welcome
- Sponsor
- Lenanrt Friis-Hansen
Covid19
Safety and Immunogenicity of the Candidate Vaccine MVA-SARS-2-S and a Booster Vaccination With a Licensed Vaccine Against COVID-19
In this phase I first-in-human clinical trial, healthy volunteers in two different dose cohorts will be vaccinated twice with the candidate vaccine MVA-SARS-2-S.
- Trial name
- NCT04569383
- Testing
- MVA-SARS-2-S vaccinations (days 0 & 28), Comirnaty
- Where
- Germany
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Universitätsklinikum Hamburg-Eppendorf
Coronavirus
COVID-2019 Testing and Vaccination Among African American and Latinx Public Housing Residents
This proposal seeks to enhance acceptability and uptake of COVID-19 testing and vaccination to engage African American and Latinx public housing residents in South Los Angeles.
- Trial name
- NCT04542395
- Testing
- Increasing Willingness and Uptake of COVID-19 Testing and Vaccination
- Where
- United States
- Volunteers
- healthy volunteers welcome
- Sponsor
- Charles Drew University of Medicine and Science
Covid19, Breakthrough Infection
Antibody After COVID-19 Vaccination
Chronic kidney disease (CKD) including patients on dialysis and kidney transplant recipients. represents the special subgroups of patients that required protection during the Severe Coronavirus Disease 2019 (COVID-19) pandemic…
- Conditions
- Covid19, Breakthrough Infection, CKD, Kidney Transplant
- Trial name
- NCT05057936
- Testing
- COVID vaccine
- Where
- Thailand
- Volunteers
- 140 people, healthy volunteers welcome
- Sponsor
- Bangkok Metropolitan Administration Medical College and Vajira Hospital
COVID-19
Evaluating Public Health Interventions to Improve COVID-19 Testing Among Underserved Populations
The COVID-19 pandemic has disproportionately affected people from underserved and vulnerable populations such as low-income/uninsured, unhoused, and immigrant communities.
- Trial name
- NCT05270694
- Testing
- Public Health Intervention Package
- Where
- 3 sites in United States
- Volunteers
- 102 people, healthy volunteers welcome
- Sponsor
- Kathleen Fairfield
Post-Acute Sequelae of SARS-CoV-2 Infection, Long COVID
Observational Study of Intranasal IVIG in Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Patients Undergoing Medical Tourism
This observational study is being conducted by Healing Hope International to collect real-world data on an emerging treatment approach for Long COVID in patients with immunodeficiency.
- Conditions
- Post-Acute Sequelae of SARS-CoV-2 Infection, Long COVID, Long COVID Fatigue, Long COVID Syndrome
- Trial name
- IVIG-LC (NCT06992401)
- Volunteers
- 50 people
- Sponsor
- Tamara C Tamas